Curated News
By: NewsRamp Editorial Staff
August 17, 2026
SCHOTT Pharma Advances Climate Action with Updated Science-Based Targets
TLDR
- SCHOTT Pharma's validated climate targets signal regulatory readiness, a competitive edge in pharma markets increasingly prioritizing sustainability.
- SCHOTT Group's SBTi-validated targets cut Scope 1&2 by 46.2% and Scope 3 by 27.5% by 2030, using absolute reductions.
- SCHOTT Pharma's science-based climate action helps protect the planet, ensuring a healthier future for global communities.
- SCHOTT Pharma switched to membrane-based WFI generation, improving water efficiency from 70% to over 90%.
Impact - Why it Matters
This news matters because it underscores the growing importance of corporate sustainability in the pharmaceutical industry. By adopting more rigorous science-based targets, SCHOTT Pharma is not only reducing its environmental footprint but also setting a precedent for other companies to follow. The shift from a focus on Scope 1 and 2 emissions to include absolute Scope 3 reductions indicates a deeper commitment to addressing the full lifecycle impacts of products. For consumers and healthcare providers, this means that the medications and packaging they rely on are being produced in a more environmentally responsible manner, contributing to global efforts to mitigate climate change. It also highlights how companies can align their operations with international climate goals, demonstrating that industrial innovation and environmental responsibility can go hand in hand.
Summary
SCHOTT Pharma, a leading provider of drug containment solutions and delivery systems, has reaffirmed its dedication to science-based climate action following the validation of the SCHOTT Group's updated climate targets by the Science Based Targets initiative (SBTi). The updated framework, which includes SCHOTT Pharma's business scope, maintains the previously validated Scope 1 and Scope 2 emissions reduction target of 46.2% by fiscal year 2030 compared to a 2019 baseline. However, it introduces a new absolute Scope 3 target, committing to a 27.5% reduction in GHG emissions from the most impactful value chain categories, including purchased goods and services, fuel- and energy-related activities, and the processing of sold products.
Reinhard Mayer, CFO of SCHOTT Pharma, emphasized that the updated Scope 3 target enables a more impact-oriented approach, focusing on emission reductions that matter most across the value chain. The company continues to prioritize sourcing Energy Attribute Certificates from renewable energies, enhancing energy efficiency, and fostering technological innovation. Notably, at its Swiss site, SCHOTT Pharma has transitioned to an advanced membrane-based system for Water for Injection generation, reducing reliance on natural gas and improving water efficiency from 70% to over 90%. The company also collaborates with suppliers and customers to lower emissions, including through initiatives like Energize and Alliance to Zero.
With the validation, SCHOTT Group and SCHOTT Pharma have discontinued their previous internal goal of 'climate neutral by 2030,' which focused solely on Scope 1 and 2 emissions and included compensation. The new science-based targets align with the Paris Agreement's goal to limit global warming to 1.5 degrees Celsius. As part of its strategy, SCHOTT Pharma evaluates suppliers' climate commitments and supports them in decarbonization efforts. Innovations in low-emission melting technologies for pharmaceutical glass tubing are crucial for reducing Scope 3.1 emissions. The company's comprehensive sustainability efforts are detailed on its website, reflecting its long-term commitment to environmental stewardship.
Source Statement
This curated news summary relied on content distributed by NewMediaWire. Read the original source here, SCHOTT Pharma Advances Climate Action with Updated Science-Based Targets
